Schrodinger reports Q1 EPS (82c) vs. (76c) last year

Reports Q1 revenue $59.6M, consensus $54.6M. “We are very pleased with Schrodinger’s (SDGR) performance in the first quarter of 2025, with strong software and drug discovery revenue growth. Our proprietary pipeline is progressing, and we are looking forward to reporting initial data from the Phase 1 clinical study of SGR-1505 next month,” said Ramy Farid, Ph.D., chief executive officer of Schrodinger. “More broadly, the pharmaceutical industry and even regulatory agencies are seeking to increase usage of computational solutions in R&D, and we continue to fortify our position as a scientific powerhouse in this field. With our growing software business and advancing pipeline of collaborative and proprietary programs, we believe we have a solid foundation that positions us for long-term growth.”